Zinc finger nucleases for targeted mutagenesis and repair of the sickle-cell disease mutation: An in-silico study.

BMC Blood Disorders
Misaki Wayengera

Abstract

Sickle cell disease (or simply, SCD) is an inherited hemoglobinopathy which is mostly prevalent among persons of African descent. SCD results from a monogenic (Hemoglobin, beta) point-mutation (substitution of the base Adenine with Thymine at position six) that leads to replacement of the amino acid glutamic acid (E) with valine (V). Management of SCD within resource-poor settings is largely syndromic, since the option of cure offered by bone-marrow transplantation (BMT) is risky and unaffordable by most affected individuals. Despite previous reports of repair and inhibition of the sickle beta-globin gene and messenger ribonucleic acids (mRNAs), respectively in erythrocyte precursor cells via gene-targeting using an oligomer-restriction enzyme construct and either ribozyme- or RNA-DNA chimeric oligonucleotides (or simply third strand binding), gene-therapy to treat SCD still remains largely preclinical. In the wake of the advances in target- gene- mutagenesis and repair wrought by zinc finger nuclease (ZFN) technology, it was hypothesized that SCD may be cured by the same. The goal of this study thus, was constructing a database of zinc finger arrays (ZFAs) and engineering ZFNs, that respectively bind and cleave within or aroun...Continue Reading

References

May 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·E G SheselyB W Popovich
Jan 5, 1989·Nature·L Luzzatto, P Goodfellow
Mar 1, 1981·Scientific American·M J Friedman, W Trager
Nov 25, 1983·Journal of Molecular Biology·B Shaanan
May 15, 1984·Journal of Molecular Biology·G FermiR Fourme
Aug 1, 1982·American Journal of Hematology·S K BallasE R Burka
Feb 6, 1996·Proceedings of the National Academy of Sciences of the United States of America·Y G KimS Chandrasegaran
Aug 8, 1996·The New England Journal of Medicine·M C WaltersK M Sullivan
Oct 13, 1998·Current Biology : CB·D J Weatherall
May 26, 1999·Gene Therapy·E B Kmiec
Mar 1, 2000·Gene Therapy·L XuB S Pace
Jun 5, 2001·Genetics in Medicine : Official Journal of the American College of Medical Genetics·A Ashley-KochC A Boyle
Feb 26, 2005·BMJ : British Medical Journal·Graham R Serjeant
Aug 6, 2005·Nature Biotechnology·Matthew H Porteus, Dana Carroll
Oct 28, 2005·Nucleic Acids Research·Sundar DuraiSrinivasan Chandrasegaran
Apr 21, 2006·The Cochrane Database of Systematic Reviews·R J Dunlop, K C L B Bennett
Jul 18, 2006·Nucleic Acids Research·Jeffrey G Mandell, Carlos F Barbas
Mar 5, 2008·Mayo Clinic Proceedings·Alan K Geller, M Kevin O'Connor
Jun 12, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Toni Cathomen, J Keith Joung
Sep 10, 2008·BMJ : British Medical Journal·Mariane de Montalembert
Sep 16, 2008·Nigerian Journal of Medicine : Journal of the National Association of Resident Doctors of Nigeria·W Misaki
Jan 21, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Janka MátraiThierry VandenDriessche
May 4, 2010·Nucleic Acids Research·Jeffry D SanderDrena Dobbs
Jun 24, 2010·BMC Blood Disorders·Andrew L OkwiJames K Tumwine
Aug 19, 2010·Nature Reviews. Genetics·Fyodor D UrnovPhilip D Gregory
Sep 17, 2010·Nature·Marina Cavazzana-CalvoPhilippe Leboulch
Dec 7, 2010·Lancet·David C ReesMark T Gladwin
Aug 9, 2011·Nature Biotechnology·Richard GabrielChristof von Kalle
Jul 1, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Toni Cathomen, J Keith Joung

❮ Previous
Next ❯

Citations

Mar 26, 2013·PLoS Computational Biology·Jan GrauJens Boch

❮ Previous
Next ❯

Methods Mentioned

BETA
one-hybrid

Software Mentioned

ZFN
CoDA
ZFA
ZiFiT
- ZFN

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.